Compare GDRX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDRX | ENGN |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Retail: Computer Software & Peripheral Equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.3M | 647.1M |
| IPO Year | 2020 | N/A |
| Metric | GDRX | ENGN |
|---|---|---|
| Price | $2.31 | $8.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $3.66 | ★ $21.08 |
| AVG Volume (30 Days) | ★ 1.3M | 245.0K |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $796,853,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.38 | N/A |
| P/E Ratio | $25.56 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.77 | $2.66 |
| 52 Week High | $5.61 | $12.25 |
| Indicator | GDRX | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.57 | 53.86 |
| Support Level | $2.11 | $7.83 |
| Resistance Level | $2.47 | $8.14 |
| Average True Range (ATR) | 0.10 | 0.55 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 68.92 | 54.89 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.